Full-Time

Sr. Global Clinical Lead

Prostate Cancer Therapeutics

Confirmed live in the last 24 hours

Telix Pharmaceuticals

Telix Pharmaceuticals

501-1,000 employees

Develops targeted radiation therapies for cancer

Biotechnology
Healthcare

Senior, Expert

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Data Analysis

You match the following Telix Pharmaceuticals's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Medical degree required
  • Clinical experience in medical oncology or nuclear medicine is essential
  • 7+ years of experience in clinical development
  • Strong knowledge of clinical trial design, methodology, and regulatory requirements required
  • Successful leadership and project management of clinical development programs required
Responsibilities
  • Lead development of clinical development plans for therapeutic assets in prostate cancer
  • Collaborate with global program heads, regulatory affairs, medical affairs, and translational medicine teams to ensure alignment of clinical trial objectives with overall asset strategy
  • Develop clinical study plans from concept to synopsis to full protocol, ensuring alignment with the Company’s objectives, and the needs of regulatory authorities, healthcare professionals, patient groups, guidelines committees and payors
  • Develop – in collaboration with relevant cross-functional teams and medical writers – clinical study documentation including, but not limited to informed consent documents, imaging charters, study manuals and final regulatory dossiers.
  • Lead clinical scientific input into documentation including investigator brochures, IMPDs, safety reports (e.g. DSURs, PSURs, and SUSARs), clinical study reports and regulatory documents such as briefing packages, INDs, BLAs, NDAs and MAAs
  • Lead the analysis, review, and quality control of clinical data (e.g. study-related, aggregated) including efficacy, safety, and imaging data to ensure accuracy and quality
  • Prepare and deliver presentations, proposals, and reports for senior management, partners, and other stakeholders
Desired Qualifications
  • Experience with regulatory submissions (e.g., IND, CTA) and interaction with regulatory agencies (e.g., FDA, EMA) is preferred
Telix Pharmaceuticals

Telix Pharmaceuticals

View

Telix Pharmaceuticals develops and sells products aimed at improving the diagnosis and treatment of cancer and rare diseases. The company focuses on creating therapeutic and diagnostic solutions that use targeted radiation, which helps healthcare providers make better treatment decisions and offers personalized therapy for patients with significant medical needs. Their product pipeline includes treatments for prostate and kidney cancers, glioma, sarcoma, and bone marrow conditioning. Telix operates a global supply chain to manufacture and distribute its products, generating revenue through sales to healthcare institutions. The company emphasizes sustainability, patient care, and ethical practices, aiming to create value for patients, shareholders, and employees.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$14.8M

Headquarters

Melbourne, Australia

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Illuccix approval in the UK and Europe boosts Telix's PSMA-PET imaging market presence.
  • Acquisition of ImaginAb's platform enhances Telix's radiotherapeutic technology and product development.
  • Partnership with Curium Pharma expands Scintimun's distribution and market penetration.

What critics are saying

  • Increased competition in PSMA-PET imaging may impact Telix's market share.
  • Integration challenges from ImaginAb acquisition could affect operational efficiency.
  • Gallium-68 supply shortages may disrupt Illuccix production and distribution.

What makes Telix Pharmaceuticals unique

  • Telix focuses on molecularly-targeted radiation therapy for prostate, renal, and glioblastoma cancers.
  • The company integrates sustainability and patient care into its biopharmaceutical operations.
  • Telix's global supply chain ensures product availability and delivery worldwide.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Annual Performance Bonus

Equity-Based Incentive Program

Paid Vacation

Paid Wellness Days

Hybrid Work Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-3%
The Manila Times
Feb 13th, 2025
Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)

Telix to showcase urology pipeline at upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025).

PR Newswire
Feb 12th, 2025
Illuccix® Approved In The United Kingdom

MELBOURNE, Australia, Feb. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection).Illuccix is indicated in the UK for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, using PET. PSMA-PET imaging[2] represents a major advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT[3] scan) as the standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR/biochemical persistence (BCP)[4].Gary Cook, MD, Professor of Molecular Imaging at Kings College London School of Biomedical Engineering & Imaging Sciences, commented, "PSMA-PET supply shortages in the UK and Europe have escalated over the past 12 months as demand increases, which has led to delays for men in urgent need of a scan to direct clinical management. It is great news that Telix can now help address this unmet need and improve equity of access in the UK through their Illuccix imaging agent and network distribution model."Raphaël Ortiz, Chief Executive Officer, Telix International added, "PSMA-PET imaging is one of the most important developments in prostate cancer detection in recent years and we are delighted that we can now bring Illuccix to physicians and their patients across the UK. A key advantage of Illuccix is that the radioisotope (gallium-68) can be produced using a generator locally, taking just a few minutes with minimal equipment

PR Newswire
Jan 22nd, 2025
ImaginAb's Biologics Platform Acquired by Telix

ImaginAb, Inc. has agreed to sell its next-generation therapeutic candidates, biologics technology platform, and research facility to Telix Pharmaceuticals. Post-transaction, ImaginAb will focus on its CD8 ImmunoPET, in Phase 2 trials, and its prostate cancer imaging agent. The sale allows Telix to explore new disease areas with radiotherapeutic technology. Jefferies LLC and Stifel, Nicolaus & Company advised on the transaction.

PR Newswire
Jan 16th, 2025
Illuccix® Receives European Approval

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP). This significant milestone follows the issuance of the Final Assessment Report from the German Competent Authority BfArM[2] as Reference Member State (RMS). Through the DCP, the RMS and all 18 European Economic Area (EEA) Concerned Member States (CMS)[3] agree that Illuccix should receive marketing authorization. The DCP regulatory process will now transition into an administrative national phase to implement authorizations to facilitate commercial launch in each country[4]. Kevin Richardson, Chief Executive Officer, Telix Precision Medicine commented, "We are delighted by this positive outcome, setting the stage for a European commercial launch of Illuccix

Precision Medicine Online
Jan 16th, 2025
Telix Pharmaceuticals Acquires Early-Stage Assets From ImaginAb, Shares Late-Stage Pipeline Updates

NEW YORK - Telix Pharmaceuticals on Monday announced plans to acquire several assets from ImaginAb, including antibodies designed to target DLL3 and integrin αvβ6 as well as several other novel targets.